IE
BBIO icon

Israel Englander’s BridgeBio Pharma BBIO Stock Holding History

Israel Englander’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,500
Closed -$206K – 5862
2024
Q4 		$206K Buy
+7,500
New +$194K ﹤0.01% 5293
2024
Q2 		– Sell
-82,500
Closed -$2.55M – 5880
2024
Q1 		$2.55M Buy
82,500
+47,500
+136% +$1.62M ﹤0.01% 3508
2023
Q4 		$1.41M Buy
+35,000
New +$1.05M ﹤0.01% 3883
2022
Q1 		– Sell
-20,000
Closed -$334K – 6896
2021
Q4 		$334K Buy
+20,000
New +$846K ﹤0.01% 5431

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Israel Englander's BBIO Position: Q2 2026 in Review

Israel Englander reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $10.2M and leaving 487,594 shares worth $36.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Israel Englander first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $47M in Q1 2026. 472 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Israel Englander held 487,594 shares of BridgeBio Pharma worth $36.3M as of Q2 2026.
  • Israel Englander sold 145,689 BridgeBio Pharma shares in Q2 2026, an estimated $10.2M.
  • BridgeBio Pharma made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1119 holding.
  • Israel Englander first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
  • Israel Englander's BridgeBio Pharma position peaked at $47M in Q1 2026.
  • 472 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.